News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
The company will provide the technical and financial resources to support the study
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Trivector Biomed has been promoting its Novaerus air disinfection solution across hospitals and health care facilities across India.
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
Biocon Biologics and Viatris co-developed the products
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
Subscribe To Our Newsletter & Stay Updated
